WuXi Biologics remains in Hang Seng ESG 50 Index
WuXi Biologics retained inclusion in the Hang Seng ESG 50 Index, extending capital-market recognition of its ESG performance. Also remained in the Hang Seng Corporate Sustainability Benchmark Index, reinforcing its sustainability positioning with investors. HKQAA awarded an A+ rating in its 2026 sustainability assessme